Source:http://linkedlifedata.com/resource/pubmed/id/12424764
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
11
|
pubmed:dateCreated |
2002-11-8
|
pubmed:abstractText |
Women having access to prenatal care late in pregnancy may still wish to benefit from maternal serum screening for Down syndrome. Therefore, we established reference values for alpha-feto protein (AFP) and free beta-human chorionic gonadotrophin (beta-hCG), and assessed the diagnostic value of maternal serum marker screening at 18-35 weeks' gestation based upon a series of 4072 sera from unaffected pregnancies and 118 sera from pregnant women with fetuses affected by Down syndrome. Using a 1/250 risk cut-off, a detection rate of 72.9% (95% CI = 71.5-74.3%) was achieved with a false-positive rate of 7.51% (95% CI = 6.71-8.3%). This was not significantly different from the percentages observed in our 14-17 weeks routine screening (50 596 patients): 71.9% (95% CI = 71.5-72.3%) and 6.48% (95% CI = 6.28-6.68%), respectively. Detection and screen-positive rates were, respectively, 51.3% (95% CI = 35.6-67.0%) and 5.95% (95% CI = 5.12-6.68%) in women aunder 35 years of age, and 84.8% (95% CI = 76.9-92.7%) and 24% (95% CI = 20.7-27.3%) in women aged 35 years and over. In conclusion, maternal serum marker screening is feasible at 18 weeks' gestation and later, which may be of interest in selected cases.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
0197-3851
|
pubmed:author | |
pubmed:copyrightInfo |
Copyright 2002 John Wiley & Sons, Ltd.
|
pubmed:issnType |
Print
|
pubmed:volume |
22
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1001-4
|
pubmed:dateRevised |
2004-11-18
|
pubmed:meshHeading |
pubmed-meshheading:12424764-Adult,
pubmed-meshheading:12424764-Biological Markers,
pubmed-meshheading:12424764-Chorionic Gonadotropin, beta Subunit, Human,
pubmed-meshheading:12424764-Down Syndrome,
pubmed-meshheading:12424764-False Positive Reactions,
pubmed-meshheading:12424764-Female,
pubmed-meshheading:12424764-Gestational Age,
pubmed-meshheading:12424764-Humans,
pubmed-meshheading:12424764-Mass Screening,
pubmed-meshheading:12424764-Maternal Age,
pubmed-meshheading:12424764-Predictive Value of Tests,
pubmed-meshheading:12424764-Pregnancy,
pubmed-meshheading:12424764-Pregnancy, High-Risk,
pubmed-meshheading:12424764-Prenatal Diagnosis,
pubmed-meshheading:12424764-Reference Values,
pubmed-meshheading:12424764-alpha-Fetoproteins
|
pubmed:year |
2002
|
pubmed:articleTitle |
Down syndrome maternal serum marker screening after 18 weeks' gestation.
|
pubmed:affiliation |
Service de Biochimie, Hôpital Ambroise Paré, Boulogne, France. francoise.muller@apr.ap-hop-paris.fr
|
pubmed:publicationType |
Journal Article
|